RxDoctor Payments Data

Kerri Rothwell

Nurse Practitioner · Hopkinton, MANPI 1568724698

Payments from drug & device makers

$2,000in general payments, 2019–2025

Across 80 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$904
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$312
  • Teva Pharmaceuticals USA, Inc.$216
  • Johnson & Johnson$203
  • Sunovion Pharmaceuticals Inc.$93
  • Axsome Therapeutics, Inc.$86
  • plus $186 from 4 others

What the payments were for

  • Food & beverage$1,94197%
  • Education$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,000 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$3,325
Medicare patients
26
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate74$232,271
Invega TrinzaPaliperidone Palmitate14$131,145
AustedoDeutetrabenazine20$115,916
VraylarCariprazine Hcl50$65,924
Risperidone ErRisperidone Microspheres13$26,025
LybalviOlanzapine/Samidorphan Malate11$16,812
Clozapine91$11,361
Aripiprazole128$8,142
Quetiapine Fumarate66$2,212
Haloperidol Decanoate42$1,963
Olanzapine97$1,904
Benztropine Mesylate101$1,687
Chlorpromazine Hcl26$1,682
Lamotrigine127$1,665
Ziprasidone Hcl51$1,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$203$363,41588 claims
Teva Pharmaceuticals USA, Inc.Austedo$216$115,91620 claims
AbbVieVraylar$904$65,92450 claims
Alkermes, Inc.Lybalvi$34$16,81211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Hopkinton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →